| Number | Title |
| 05-21 | A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed By Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer |
| 04-15 | A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients With Favorable-Risk Prostate Cancer |
| 03-21 | Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate |
| 00-19 | A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate |
| 00-11 | Phase III Randomized Study of Adjuvant Therapy for High Risk pT2-3N0 Prostate Cancer |
| 99-10 | A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer |
| 99-02 | A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs. AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk Prostate Cancer |
| 98-05 | A Phase II Trial of Transrectal Ultrasound-Guided Permanent Radioactive Implantation of the Prostate For Definitive Management of Localized Adenocarcinoma of the Prostate |
| 97-14 | Randomized Trial of Palliative Radiation Therapy For Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life |
| 96-08 | A Phase III Trial of Total Androgen Suppression vs. Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive (pN+) Adenocarcinoma of the Prostate |
| 96-01 | A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy For pT3N0 Carcinoma of the Prostate |
| 94-13 | A Phase III Trial Comparing Whole Pelvic Irradiation Followed by a Conedown Boost to Boost Irradiation Only and Comparing Neoadjuvant to Adjuvant Total Androgen Suppression (TAS) |
| 94-08 | A Phase III Trial of the Study of Endocrine Therapy Used As a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy In Good Prognosis Locally Confined Adenocarcinoma of the Prostate |
| 94-06 | A Phase I/II Dose Escalation Study Using 3D-CRT for Adenocarcinoma of the Prostate |
| 92-02 | Phase III Randomized Trial of Long-Term Adjuvant Total Androgen Suppression with ZDX vs No Subsequent Treatment Following Neoadjuvant FLUT/ZDX and Radiotherapy for Locally Advanced Carcinoma of the Prostate |
| 90-20 | A Phase II Trial of External Beam Radiation With Etanidazole for Locally Advanced Prostate Cancer |
| 90-19 | A Phase III Study of the Treatment of Pathologic Stage C Carcinoma of the Prostate With Adjuvant Radiotherapy |
| 88-22 | Phase I/II Study of Fractionated Hemibody Irradiation to Treat Osseous Metastases in Patients with Primaries of the Breast or Prostate |
| 86-10 | Phase III Study of Androgen Deprivation Adjuvant to Definitive Radiotherapy in Locally Advanced Carcinoma of the Prostate |
| 85-31 | Phase III Comparison of Adjuvant Therapy with Zoladex vs Observation Only Following Definitive Radiotherapy for Unfavorable Prognosis Adenocarcinoma of the Prostate |
| 85-19 | Unknown title - Phase II Flutamide and Zoladex prior to and during radiotherapy |
| 83-07 | Phase II Megestrol Acetate vs Diethylstilbestrol Adjuvant to Radiotherapy for Locally Advanced Stage B/C Carcinoma of the Prostate |
| 77-06 | Phase III Prostatic Irradiation vs Pelvic Irradiation plus Prostate Boost for Stage A2/B Prostatic Adenocarcinoma |
| 75-06 | Phase III Pelvic Irradiation vs Pelvic and Para-aortic Irradiation for Stage A2/B/C Adenocarcinoma of the Prostate |